Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2011.04082.xPMID 21834938PMCID PMC3269582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Central obesity and multivariable cardiovascular risk as assessed by the Framingham prediction scores.

  2009cited by this paper
• Blood pressure changes associated with sibutramine and weight management – an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes trial (SCOUT) *

  2009cited by this paper
• Antiobesity Surgery in Sweden From 1980 to 2005: A Population-Based Study With A Focus on Mortality

  2008cited by this paper
• Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study

  2008cited by this paper
• Distribution of Peripherally Injected Peptide YY ([125I] PYY (3–36)) and Pancreatic Polypeptide ([125I] hPP) in the CNS: Enrichment in the Area Postrema

  2007cited by this paper
• Long term pharmacotherapy for obesity and overweight: updated meta-analysis

  2007cited by this paper
• Low-dose pancreatic polypeptide inhibits food intake in man

  2007cited by this paper
• overweight: updated meta-analysis Long term pharmacotherapy for obesity and

  2007cited by this paper
• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  2007cited by this paper
• The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.

  2003cited by this paper
• Pancreatic polypeptide reduces appetite and food intake in humans.

  2003cited by this paper
• Distribution of pancreatic polypeptide and peptide YY.

  2002cited by this paper
• Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

  2000cited by this paper
• Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

  2000cited by this paper
• Obesity as a medical problem

  2000cited by this paper
• Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

  2000cited by this paper
• The SCOFF questionnaire: assessment of a new screening tool for eating disorders

  1999cited by this paper
• Cloning of a Human Receptor of the NPY Receptor Family with High Affinity for Pancreatic Polypeptide and Peptide YY (*)

  1995cited by this paper
• Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party

  1995cited by this paper
• Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men

  1994cited by this paper
• BODY MASS INDEX VERSUS HEIGHT AND WEIGHT IN RELATION TO BLOOD PRESSURE FINDINGS FOR THE 10,079 PERSONS IN TEE INTERSALT STUDY

  1990cited by this paper
• Body mass index versus height and weight in relation to blood pressure. Findings for the 10,079 persons in the INTERSALT Study.

  1990cited by this paper
• The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior

  1986cited by this paper
• Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations.

  1980cited by this paper
• Pharmacokinetics of pancreatic polypeptide in man.

  1978cited by this paper
• Distribution and release of human pancreatic polypeptide.

  1976cited by this paper

• Illuminating the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic perspective.

  2024cites this paper
• Obesity is associated with impaired postprandial pancreatic polypeptide secretion

  2023cites this paper
• Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management

  2023cites this paper
• The pancreas from a surgical perspective: an illustrated overview

  2022cites this paper
• With Obesity Becoming the New Normal, What Should We Do?

  2019cites this paper
• No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century

  2018cites this paper
• Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases

  2017cites this paper
• Identification and Characterization of the First Selective Y4 Receptor Positive Allosteric Modulator.

  2017cites this paper
• Peptide Therapeutics for Weight Loss: Preventing Plasma Pancreatic Polypeptide Proteolysis.

  2017cites this paper
• GI Peptides, Energy Balance, and Cancer

  2017cites this paper
• C-terminal motif of human neuropeptide Y4 receptor determines internalization and arrestin recruitment.

  2017cites this paper
• Gastrointestinal hormones and their role in obesity

  2016cites this paper
• Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake

  2016cites this paper
• The role of pancreatic polypeptide in the regulation of energy homeostasis.

  2015cites this paper
• Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones

  2015cites this paper
• New perspectives on the development of antiobesity drugs.

  2015cites this paper
• Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

  2014cites this paper
• Neuroendocrinology of obesity.

  2014cites this paper
• The role of the gastrointestinal tract in the control of energy balance

  2014influential citation
• Models and Strategies in the Development of Antiobesity Drugs

  2014cites this paper
• Can Bayliss and Starling gut hormones cure a worldwide pandemic?

  2014cites this paper
• Emerging Pharmacotherapies to Fight Obesity and Related Disorders

  2014cites this paper
• The future role of gut hormones in the treatment of obesity

  2014cites this paper
• Novel approaches to the pharmacotherapy of obesity.

  2013cites this paper
• Gut hormones as therapeutic agents in treatment of diabetes and obesity.

  2013cites this paper
• Gut hormones and obesity: physiology and therapies.

  2013cites this paper
• Food intake and gut hormones

  2013cites this paper
• Pharmacological characterisation of selective Y4 and dual Y2/Y4 receptor agonists : novel targets for putative anti-obesity therapies

  2013cites this paper
• Chapter 176 – Pancreatic Polypeptide

  2013cites this paper
• Manque de sommeil et maladies métaboliques

  2013cites this paper
• A novel peptide nanomedicine for treatment of pancreatogenic diabetes.

  2013cites this paper
• Treating the obese diabetic

  2013cites this paper
• A Novel Anti-Diabetic Peptide Nanomedicine Against Pancreatogenic Diabetes

  2012cites this paper
• The role of the gut/brain axis in modulating food intake.

  2012cites this paper
• Peptide delivery using phospholipid micelles.

  2012cites this paper
• Bowels control brain: gut hormones and obesity

  2012cites this paper
• Gut hormones: the future of obesity treatment?

  2012cites this paper